Loading
A phase 1 trial of ReT01 ACT run by Beijing Xunsheng Biomedical Research Co., Ltd., now recruiting.
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors is a phase 1 interventional study registered as NCT06257680 by Beijing Xunsheng Biomedical Research Co., Ltd., with 15 participants planned, started 2024-04-08. Conditions recorded: Advanced Solid Tumor. Interventions recorded: ReT01 ACT.
Shares Beijing Xunsheng Biomedical Research and the tag pipeline.
Shares Beijing Xunsheng Biomedical Research and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/